Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients.

More recently, alternative splicing of specific genes are investigated for their therapeutic potential. In particular, we reported the existence of BCR-ABL alternative splicing isoforms, in about 80% of Philadelphia-positive patients, which lead to the expression of aberrant proteins. These fusion proteins are characterized by an orphan initial and correct Bcr portion attached to a 112 amino acid sequence, arising from the impairment in the reading frame (reading of ABL exon 4 and 5). We demonstrated that these Abl-out-of-frame (OOF) isoforms could have an immunological role with therapeutic implications. The aim of this study was to characterize a new monoclonal antibody (MAb) specific for Abl-OOF protein portion, for diagnostic use, to detect this biomarker in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) patients and to generate novel approaches in the immunotherapy. 5F11G11 MAb recognizes the OOF protein portion of the native full-length Bcr/Abl-OOF protein expressed in cells transiently transfected, as demonstrated by immunoprecipitation and immunofluorescence. In addition, we demonstrate the MAb's ability to recognize the alternative hybrid Bcr/Abl fusion protein expressed in leukemic cells from CML patients, to support the possible use of 5F11G11 MAb as a diagnostic tool to select patients with Philadelphia chromosome-positive CML that could be eligible for an immunotherapeutic approach with this new antigen.

[1]  T. Brümmendorf,et al.  Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. , 2014, Blood.

[2]  C. Schürch,et al.  Dendritic Cell-Based Immunotherapy for Myeloid Leukemias , 2013, Front. Immunol..

[3]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[4]  R. Larson,et al.  Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance , 2013, Leukemia.

[5]  N. Cross,et al.  Standardized definitions of molecular response in chronic myeloid leukemia , 2012, Leukemia.

[6]  G. Saglio,et al.  Immunologic Evaluation of Peptides Derived From BCR/ABL-Out-of-Frame Fusion Protein in HLA A2.1 Transgenic Mice , 2012, Journal of immunotherapy.

[7]  R. Longhi,et al.  Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins. , 2011, Hybridoma.

[8]  C. Panuzzo,et al.  Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. , 2009, Cancer letters.

[9]  D. Cilloni,et al.  Imatinib resistance in CML. , 2009, Cancer letters.

[10]  G. Perrone,et al.  Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. , 2007, Cancer research.

[11]  S. Güller,et al.  BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility , 2006, BMC Cancer.

[12]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[13]  M. Nakazawa,et al.  Production and purification of monoclonal antibodies. , 2010, Methods in molecular biology.

[14]  B. Savani,et al.  Does chemotherapy modify the immune surveillance of hematological malignancies? , 2009, Leukemia.